For the quarter ended June 2026, Sotera Health Company (SHC) reported revenue of $321.38 million, up 9.2% over the same period last year. EPS came in at $0.26, compared to $0.20 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $311.13 million, representing a surprise of +3.29%. The company delivered an EPS surprise of +8.33%, with the consensus EPS estimate being $0.24.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Sotera Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Net Revenues- Sterigenics: $211.57 million compared to the $208.83 million average estimate based on three analysts. The reported number represents a change of +8.6% year over year.
  • Net Revenues- Nelson Labs: $60.66 million compared to the $58.14 million average estimate based on three analysts. The reported number represents a change of +6.3% year over year.
  • Net Revenues- Nordion: $49.15 million versus the three-analyst average estimate of $43.92 million. The reported number represents a year-over-year change of +15.8%.
  • Segment Income- Sterigenics: $118.13 million versus the three-analyst average estimate of $113.88 million.
  • Segment Income- Nelson Labs: $19.63 million versus $18.56 million estimated by three analysts on average.
  • Segment Income- Nordion: $27.98 million versus $24.09 million estimated by three analysts on average.

View all Key Company Metrics for Sotera Health here>>>

Shares of Sotera Health have returned +2.9% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. 

See them now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Sotera Health Company (SHC): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research